.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Teva
Farmers Insurance
AstraZeneca
Queensland Health
McKesson
QuintilesIMS
Federal Trade Commission
Covington
US Army

Generated: September 24, 2017

DrugPatentWatch Database Preview

GELNIQUE Drug Profile

« Back to Dashboard

What is the patent landscape for Gelnique, and when can generic versions of Gelnique launch?

Gelnique is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-four patent family members in twenty countries.

The generic ingredient in GELNIQUE is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.

Summary for Tradename: GELNIQUE

Patents:5
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list100
Clinical Trials: see list3
Patent Applications: see list1,350
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GELNIQUE at DailyMed

Pharmacology for Tradename: GELNIQUE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE 3%
oxybutynin
GEL, METERED;TRANSDERMAL202513-001Dec 7, 2011DISCNYesNo► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE 3%
oxybutynin
GEL, METERED;TRANSDERMAL202513-001Dec 7, 2011DISCNYesNo► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
GELNIQUE 3%
oxybutynin
GEL, METERED;TRANSDERMAL202513-001Dec 7, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Sales Llc
GELNIQUE 3%
oxybutynin
GEL, METERED;TRANSDERMAL202513-001Dec 7, 2011DISCNYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for GELNIQUE

Drugname Dosage Strength RLD Submissiondate
oxybutynin chlorideGel10%Gelnique6/19/2014

Non-Orange Book Patents for Tradename: GELNIQUE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,743,441 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
7,081,252Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
7,081,251Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
7,081,250Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
7,081,249Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GELNIQUE

Country Document Number Estimated Expiration
European Patent Office1992342► Subscribe
Canada2760867► Subscribe
Norway20052625► Subscribe
South Korea20110043725► Subscribe
European Patent Office2427172► Subscribe
Japan2003531157► Subscribe
MexicoPA02010542► Subscribe
European Patent Office1565136► Subscribe
Japan6077294► Subscribe
China102421411► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
McKinsey
Federal Trade Commission
Deloitte
Covington
AstraZeneca
Chinese Patent Office
Cerilliant
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot